Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Hickman RA, Hughes D, Cars T, Malmberg C, Cars O.

Clin Microbiol Infect. 2014 Apr;20(4):O267-73. doi: 10.1111/1469-0691.12374.

2.

Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O.

Antimicrob Agents Chemother. 2014;58(3):1757-62. doi: 10.1128/AAC.00741-13.

3.

Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.

Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2012 May;31(5):695-701. doi: 10.1007/s10096-011-1360-5.

PMID:
21805292
5.

Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.

Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G.

Int J Antimicrob Agents. 2010 Mar;35(3):240-3. doi: 10.1016/j.ijantimicag.2009.10.019.

PMID:
20034765
6.
7.

[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].

de Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual A.

Enferm Infecc Microbiol Clin. 2006 Dec;24(10):613-6. Spanish.

PMID:
17194386
8.

In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.

Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA.

Chemotherapy. 2003 May;49(1-2):44-8.

PMID:
12714810
9.

In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae.

Netikul T, Leelaporn A, Leelarasmee A, Kiratisin P.

Int J Antimicrob Agents. 2010 Jun;35(6):609-10. doi: 10.1016/j.ijantimicag.2010.01.021. No abstract available.

PMID:
20189774
10.
12.
13.
14.

Oral antibiotics for infections due to multidrug-resistant Gram-negative organisms.

Glasser JS, Markelz AE, Zera WC, Beckius ML, Mende K, Murray CK.

Scand J Infect Dis. 2011 Aug;43(8):649-51. doi: 10.3109/00365548.2011.572908.

PMID:
21466257
16.

Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.

Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, Panagea T, Argyropoulou A, Stefanou I, Plakias G, Giamarellou H, Petrikkos G.

J Chemother. 2012 Aug;24(4):191-4. doi: 10.1179/1973947812Y.0000000015.

17.
18.

Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.

Wang P, Hu F, Xiong Z, Ye X, Zhu D, Wang YF, Wang M.

J Clin Microbiol. 2011 Sep;49(9):3127-31. doi: 10.1128/JCM.00222-11.

19.

Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.

Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A.

Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031.

PMID:
21236643
20.

[Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].

Xiong Z, Zhu D, Zhang Y, Wang F.

Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1476-9. Chinese.

PMID:
12509910
Items per page

Supplemental Content

Support Center